Skip to main content

Lower Limb Ischemia

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Boston Scientific
Boston ScientificCA - Valencia
1 program
1
Ranger SL DEBPhase 2/31 trial
Active Trials
NCT02856230Unknown30Est. Nov 2018
Tissue Genesis
Tissue GenesisTX - Leander
1 program
ASC coated ePTFE vascular graftN/A1 trial
Active Trials
NCT01305863Unknown60Est. May 2022
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
ASC coated ePTFE vascular graftN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boston ScientificRanger SL DEB
Tissue GenesisASC coated ePTFE vascular graft

Clinical Trials (2)

Total enrollment: 90 patients across 2 trials

An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)

Start: Nov 2016Est. completion: Nov 201830 patients
Phase 2/3Unknown
NCT01305863Tissue GenesisASC coated ePTFE vascular graft

Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft

Start: Feb 2011Est. completion: May 202260 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.